Brittany Craiglow, MD
Associate Professor Adjunct - DermatologyCards
About
Research
Publications
2024
Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 1-1. PMID: 39404927, DOI: 10.1007/s13555-024-01265-2.Peer-Reviewed Original ResearchBH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
O’Connor C, Asfour L, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Meah N, Ohyama M, Ovcharenko J, Primez R, Piraccini B, Rudnicka L, Corralo D, Shapiro J, Sinclair R, Smith B, Starace M, Galvan S, Wang K, York K, McDonald I, Wall D. BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists. British Journal Of Dermatology 2024, 191: i74-i75. DOI: 10.1093/bjd/ljae090.151.Peer-Reviewed Original ResearchLiver function testsFunction testsHIV testingHepatitis BLipid testingAlopecia areataSeverity of Alopecia ToolScreening bloodHair disordersRenal function testsRisk of cardiovascular diseaseJanus kinase inhibitorsDermatology Life Quality IndexJanus kinaseBritish Association of DermatologistsLife Quality IndexLaboratory testsHair loss disorderSystemic therapyThyroid testsIdentification of comorbiditiesImmune-mediatedRenal functionThyroid diseaseAssociation of DermatologistsImprovement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 1959-1968. PMID: 38904749, PMCID: PMC11265044, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQoLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost hoc analysisDisease associated with high ratesDepressionScoresThe Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease durationIn‐person validation of the Ichthyosis Scoring System
Echeandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.Peer-Reviewed Original ResearchInterrater intraclass correlation coefficientsIntrarater reliabilityIn-personIntraclass correlation coefficientIn-person evaluationContent validityInterrater reliabilityHeterogeneous group of skin disordersGroup of skin disordersIntraraterMedical professionalsInterrater agreementErythema evaluationIchthyosis subtypesPhotographic evaluationErythema scoreInterraterErythemaQuantify severitySkin disordersClinical utilityIchthyosisScoring systemHeterogeneous groupCorrelation coefficient
2023
Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2
Mayo T, Taylor S, Ito T, Vañó-Galván S, Ball S, Lu N, Chiasserini C, Chen Y, Craiglow B, Leveque C. Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a336. DOI: 10.1016/j.fander.2023.09.579.Peer-Reviewed Original ResearchImprovement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covarianceWhen to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, Sinclair R, Chen Y, Wu W, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal Of Dermatology 2023, 189: 666-673. PMID: 37708254, DOI: 10.1093/bjd/ljad253.Peer-Reviewed Original ResearchSevere alopecia areataBaricitinib-treated patientsPhase III trialsAlopecia areataResponder subgroupBaricitinib 4Hair regrowthIII trialsGrowth mixture modellingTreatment expectationsLate respondersEarly respondersBaseline disease characteristicsTreatment of adultsSALT scoreWeek 52Baseline characteristicsClinical outcomesDisease characteristicsTreatment allocationHair lossPatientsResponse subgroupsRespondersSubgroupsClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Mayo T, Taylor S, Ito T, Galván S, Ball S, Lu N, Chiasserinio C, Chen Y, Craiglow B. 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2. Journal Of The American Academy Of Dermatology 2023, 89: ab42. DOI: 10.1016/j.jaad.2023.07.173.Peer-Reviewed Original Research